Step 1 of 2
Downloadable pocket guide to assist oncology nurses in quickly identifying and assessing the severity of ADC-related adverse events associated with sacituzumab govitecan and datopotamab deruxtecan in the management of patients with HR-positive, HER2-negative metastatic breast cancer, including the evolving nursing role, factors that nurses should consider to deliver safe and high-quality care, measures to use to optimize the early recognition of adverse events, and institute early intervention to improve adherence while utilizing shared treatment decision-making approaches to optimize treatment outcomes.